Neuroimaging and blood markers as indicators of ketamine efficacy in treatment resistant depression

Description of the granted funding

Major Depressive Disorder (MDD) is a highly disabling chronic disease where 30% of patients show treatment resistance (TRD), rendering it the leading cause of disability worldwide (WHO 2018). The FDA approved Spravato (esketamine) nasal spray for the treatment of depression in TRD patients in March, 2019 leading to increased patient requests and a need for clinical decision support. Increased demand for Ketamine for TRD needs to be balanced by relevant side effects and potential risk of abuse. Currently, clinical decisions lack estimation on patients' individual benefit which is only expected to see responses in 50%. This project aims to validate antidepressant response biomarkers focusing on peripheral and central mechanisms involved in synaptic plasticity and BDNF. Focusing on a fundamental pathophysiological signature, we will contribute to stratification and response monitoring using the latest technological advances in clinical research in TRD, proteomics and neuroimaging.
Show more

Starting year

2020

End year

2024

Granted funding

Eleanor Coffey Orcid -palvelun logo
303 132 €

Funder

Research Council of Finland

Funding instrument

Kansainvälinen yhteisrahoitteinen ohjelma

Other information

Funding decision number

334776

Fields of science

Biomedicine

Research fields

Biolääketieteet

Identified topics

brain, neuroscience